MARKET

MRKR

MRKR

TAPIMMUNE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.850
+0.170
+6.34%
After Hours: 2.895 +0.045 +1.58% 18:46 11/19 EST
OPEN
2.700
PREV CLOSE
2.680
HIGH
2.890
LOW
2.660
VOLUME
404.41K
TURNOVER
--
52 WEEK HIGH
9.17
52 WEEK LOW
2.610
MARKET CAP
130.16M
P/E (TTM)
-0.7238
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRKR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MRKR News

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.14h ago
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.4d ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.5d ago
  • FCEL, I, SENS, RWLK and MRKR among midday movers
  • Seeking Alpha - Article.6d ago

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About MRKR

Marker Therapeutics, Inc., formerly TapImmune Inc., is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. It combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. Its core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.
More

Webull offers Marker Therapeutics Inc (MRKR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.